MYO · XBRL financial data

Myomo financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MYO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	5,080	4,756*	3,754	7,521	9,208	12,068*	9,832	9,652	10,091	11,353*	10,113	11,705
Cost of revenue	1,591	1,652*	1,455	2,195	2,262	3,453*	3,222	3,600	3,648	3,569*	3,212	3,262
Cost of goods and services sold	33	(12)*	112	122	107	76*	32	60	98	2*	60	73
Gross profit	3,489	3,105*	2,299	5,326	6,946	8,615*	6,610	6,052	6,442	7,784*	6,902	8,443
Research and development	717	878*	956	1,007	1,249	1,560*	1,790	2,001	1,528	1,625*	1,623	1,720
Selling, general and administrative	4,796	4,660*	—	—	—	—	—	—	—	—	—	—
General and administrative	2,409	2,307*	2,870	2,656	3,253	3,604*	3,944	3,407	3,178	3,432*	3,619	3,712
Total operating expenses	5,513	5,538*	6,188	6,441	7,903	8,861*	10,130	10,642	9,960	10,558*	10,059	10,697
Other operating income (expense)	(0)	5*	0	0	0	0*	—	—	—	—	—	—
Operating income (loss)	(2,024)	(2,433)*	(3,889)	(1,115)	(958)	(245)*	(3,520)	(4,590)	(3,518)	(2,774)*	(3,157)	(2,254)
Other income (expense)	42	44*	135	107	76	70*	192	107	(10)	(956)*	334	(1,735)
Income tax expense (benefit)	46	71*	82	114	85	85*	137	148	136	84*	187	31
Net income (loss)	(2,029)	(2,460)*	(3,836)	(1,122)	(966)	(260)*	(3,465)	(4,632)	(3,663)	(3,814)*	(3,009)	(4,021)
Earnings per share, basic USD per share	(0.06)	(0.08)*	(0.10)	(0.03)	(0.03)	(0.01)*	(0.08)	(0.11)	(0.09)	(0.09)*	(0.07)	(0.09)
Earnings per share, diluted USD per share	(0.06)	(0.08)*	(0.10)	(0.03)	(0.03)	(0.01)*	(0.08)	(0.11)	(0.09)	(0.09)*	(0.07)	(0.09)
Weighted average shares, basic thousands of shares	35,266	30,410*	36,753	37,368	37,951	38,949*	41,454	41,583	42,168	42,205*	42,269	42,697
Weighted average shares, diluted thousands of shares	35,266	30,410*	36,753	37,368	37,951	38,949*	41,454	41,583	42,168	42,205*	42,269	42,697

Balance sheet

CSV

Fiscal quarters (MYO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	6,912	6,871	5,435	5,846	6,623	24,372	19,794	14,240	12,554	14,132	11,396	11,219
Short-term investments	4,209	1,995	5,524	3,136	0	493	1,730	1,242	0	4,262	4,300	2,233
Accounts receivable	2,517	2,383	1,683	2,526	3,729	3,825	4,663	7,055	5,293	4,096	4,825	4,946
Inventory	1,485	1,804	2,386	2,601	3,384	3,166	3,369	4,126	3,645	3,123	3,548	3,169
Prepaid and other current assets	920	599	677	1,032	969	933	1,541	1,382	1,458	1,944	1,588	2,958
Total current assets	16,042	13,651	15,705	15,142	14,704	32,790	31,097	28,044	22,949	27,557	25,658	24,526
Property and equipment, net	172	176	206	289	561	1,330	1,842	2,909	3,715	2,213	2,243	1,987
Right-of-use asset	716	664	605	539	467	7,585	7,296	7,058	6,870	6,679	6,499	6,514
Total assets	17,054	14,582	16,521	16,190	16,313	42,244	40,867	38,672	34,077	38,637	36,754	35,342
Current portion of long-term debt	—	—	—	—	—	2,955	—	167	583	2,955	2,733	447
Total current liabilities	5,778	5,477	5,557	6,465	6,991	10,172	11,675	11,754	9,202	8,345	9,385	10,610
Lease liability, non-current	253	115	65	47	29	7,358	7,505	7,970	7,833	7,666	7,441	7,206
Total liabilities	6,031	5,592	5,621	6,513	7,021	17,530	19,180	21,057	19,452	27,233	27,752	29,513
Accumulated deficit	(94,471)	(96,931)	(100,766)	(101,888)	(102,854)	(103,115)	(106,580)	(111,212)	(114,874)	(118,688)	(121,698)	(125,719)
Total stockholders' equity	11,023	8,989	10,900	9,678	9,292	24,714	21,687	17,615	14,626	11,403	9,002	5,829
Total liabilities and equity	17,054	14,582	16,521	16,190	16,313	42,244	40,867	38,672	34,077	38,637	36,754	35,342
Common shares outstanding (cover page) thousands of shares	26,516	28,487	28,815	30,226	30,246	34,381	35,979	37,801	38,436	38,512	38,639	39,608

Cash flows

CSV

Fiscal quarters (MYO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,029)	(2,460)*	(3,836)	(1,122)	(966)	(260)*	(3,465)	(4,632)	(3,663)	(3,814)*	(3,009)	(4,021)
Stock-based compensation	330*	334*	320	(92)*	324*	322*	540	395*	584*	565*	597	1,043*
Net cash from operating activities	(1,715)*	(2,356)*	(3,246)	(1,916)*	(1,494)*	3,366*	(2,677)	(8,865)*	(1,829)*	(1,140)*	(2,197)	(1,944)*
Purchases of property and equipment	54*	32*	60	119*	321*	860*	671	1,257*	1,053*	(1,239)*	328	32*
Net cash from investing activities	(1,315)*	2,294*	(3,543)	2,331*	2,825*	(1,353)*	(1,896)	(757)*	190*	(4,594)*	(494)	2,022*
Net cash from financing activities	3,950*	0*	5,362	0*	(200)*	15,770*	(37)	4,000*	(50)*	7,514*	0	(244)*
Net change in cash	905*	(40)*	(1,437)	411*	1,152*	17,750*	(4,579)	(5,553)*	(1,687)*	1,778*	(2,736)	(177)*

Compare with peers

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Myomo	11,219	11,705	(1,944)*	39.6M	6.9 quarters	Q2 FY26 10-QJun 30, 2026
Edap TMS	21,542	13,203	(3,691)*	37.5M	6.5 quarters	Q2 FY26 10-QJun 30, 2026
Orchestra BioMed Holdings	20,472	88	(19,332)*	60.1M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
InspireMD	15,149	1,771	(10,895)*	46.5M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Cytosorbents	4,413	9,633	(583)*	62.8M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Pro Dex	11,759	20,560	6,490	3.2M	—	Q1 FY27 10-QSep 30, 2026
Monogram Technologies	12,834	not reported	(2,297)*	40.6M	5.6 quarters	Q2 FY25 10-QJun 30, 2025
Sensus Healthcare	15,186	2,290	(3,133)*	16.5M	4.8 quarters	Q2 FY26 10-QJun 30, 2026
Mobia Medical	177,090	13,505	(15,670)*	33.3M	11.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.